{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:07:19Z","timestamp":1781626039906,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Effective, safe, and accessible antivirals are needed to treat pregnant\/postpartum (obstetric) patients with COVID-19, a group at high risk for severe disease. Newer antivirals (nirmatrelvir\/ritonavir, remdesivir) are expensive and less accessible in low- and middle-income countries, including Brazil. Oseltamivir, a cheap, widely available, pregnancy-safe anti-influenza medication, was used off-label for COVID-19 in Brazil. The primary outcome was comparing in-hospital all-cause mortality in hospitalised obstetric patients with COVID-19 treated with oseltamivir versus no antivirals. Secondary outcomes were comparing the risk of progression to severe disease (ICU admission or death, whichever occurred first) and hospital discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective matched cohort study using Brazil\u2019s national surveillance database (SIVEP-Gripe), we identified hospitalised obstetric patients with PCR-confirmed COVID-19 between February 2020 and October 2023. Patients first receiving oseltamivir on day zero of admission and admitted within seven days of symptom onset were matched 1:1 using propensity scores to patients receiving no antivirals at all.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After matching, 445 oseltamivir recipients and 445 controls were included, of whom 79.5% and 80.0%, respectively, were admitted in 2020, and 65.8% and 67.9% had non-severe COVID-19 on admission (SpO2\u2009&gt;\u200994%). Oseltamivir use was associated with a lower risk of in-hospital death (hazard ratio [HR] 0.77; [95% CI 0.51\u20131.17],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.22; absolute risk reduction [ARR] 3.9%) and progression to severe disease (HR 0.83 [95% CI [0.67\u20131.01],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07; ARR 4.5%) compared with no antivirals, though these associations were not statistically significant overall. Oseltamivir recipients were less likely to be discharged on days 0\u20132 (HR 0.68 [0.52\u20130.90]) but more likely to be discharged on or after day 3 (HR 1.30 [1.10\u20131.54]) than controls. Significant associations between oseltamivir use and lower in-hospital mortality were observed in two subgroups: patients admitted in 2020 (HR 0.54 [95% CI 0.32\u20130.93],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) and patients with non-severe COVID-19 (SpO2\u2009&gt;\u200994%) on admission (HR 0.33 [95% CI 0.12\u20130.89],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In obstetric patients with COVID-19, oseltamivir used within seven days of symptom onset was associated with non-statistically significant lower risk of in-hospital death and progression to severe disease, compared with no antivirals. Results of this study do not support use of oseltamivir to treat COVID-19 in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12327-x","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T04:43:56Z","timestamp":1766205836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of oseltamivir in hospitalised obstetric patients with COVID-19: a retrospective cohort study using a Brazilian national database"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1127-7991","authenticated-orcid":false,"given":"Angela","family":"Burvill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-3882","authenticated-orcid":false,"given":"Ana Cristina","family":"Sim\u00f5es e Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-4513","authenticated-orcid":false,"given":"Char","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0919-3462","authenticated-orcid":false,"given":"Li","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"12327_CR1","unstructured":"World Health Organisation. Therapeutics and COVID-19: living guideline. November 10 2023. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2023.2. Accessed 1 Dec 2024."},{"key":"12327_CR2","unstructured":"National Institute for Health and Care Excellence (United Kingdom). Therapeutics for people with COVID-19. https:\/\/www.nice.org.uk\/guidance\/ta878\/documents\/final-appraisal-determination-document. Accessed 1 Dec 2024."},{"key":"12327_CR3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/pds.5440","volume":"31","author":"W Westhoff","year":"2022","unstructured":"Westhoff W, Smith L, Wyszynski D, Hernandez-Diaz S. COVID-19 pharmacotherapy utilization patterns during pregnancy: international registry of coronavirus exposure in pregnancy. Pharmacoepidemiol Drug Saf. 2022;31:804\u201309. https:\/\/doi.org\/10.1002\/pds.5440.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"12327_CR4","doi-asserted-by":"publisher","unstructured":"Lassi Z, Ali A, Das J, et al. A systematic review and meta-analysis of data on pregnant women with confirmed COVID-19: clinical presentation, and pregnancy and perinatal outcomes based on COVID-19 severity. J Glob Health. 2021;11:10. https:\/\/doi.org\/10.7189\/jogh.11.05018","DOI":"10.7189\/jogh.11.05018"},{"key":"12327_CR5","unstructured":"Ministry of Health (Brazil). Manual de recomenda\u00e7\u00f5es para a assist\u00eancia \u00e0 gestante e pu\u00e9rpera frente \u00e0 pandemia de COVID-19. 2020. https:\/\/www.gov.br\/saude\/pt-br\/assuntos\/covid-19\/publicacoes-tecnicas\/guias-e-planos\/manual-instrutivo-para-a-assistencia-a-gestante-e-puerpera-frente-a-pandemia-da-covid-19\/view. Accessed 1 Dec 2024."},{"key":"12327_CR6","unstructured":"Ministry of Health (Brazil). Manual de recomenda\u00e7\u00f5es para a assist\u00eancia \u00e0 gestante e pu\u00e9rpera frente \u00e0 pandemia de COVID-19. 2021. 2\u02da edi\u00e7\u00e3o. https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/manual_assistencia_gestante_puerpera_covid-19_2ed.pdf. Accessed 1 Dec 2024."},{"key":"12327_CR7","doi-asserted-by":"publisher","unstructured":"Tan J, Yuan Y, Xu C, et al. A retrospective comparison of drugs against COVID-19. Virus Res. 2021;294:7. https:\/\/doi.org\/10.1016\/j.virusres.2020.198262","DOI":"10.1016\/j.virusres.2020.198262"},{"issue":"2","key":"12327_CR8","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1097\/AOG.0000000000005479","volume":"143","author":"American College of Obstetricians and Gynaecologists (ACOG)","year":"2024","unstructured":"American College of Obstetricians and Gynaecologists (ACOG). Influenza in pregnancy: prevention and treatment: ACOG Committee Statement No. 7. Obstet Gynecol. 2024;143(2):e24\u201330.","journal-title":"Obstet Gynecol"},{"key":"12327_CR9","unstructured":"Centers for Disease Control and Prevention (U.S). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. (Last updated September 15, 2022). https:\/\/www.cdc.gov\/flu\/hcp\/antivirals\/treatment_obstetric.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/avrec_ob.htm. Accessed 1 Dec 2024."},{"key":"12327_CR10","doi-asserted-by":"publisher","unstructured":"Adlhoch C, Delgado-Sanz C, Carnahan A, et al. Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries &, 2010 to 2020. Euro Surveill. 2023;28(4):11. https:\/\/doi.org\/10.2807\/1560-7917.ES.2023.28.4.2200340","DOI":"10.2807\/1560-7917.ES.2023.28.4.2200340"},{"key":"12327_CR11","doi-asserted-by":"publisher","unstructured":"Leung C, Su L, Taylor L, Ara\u00fajo Oliveira E, Sim\u00f5es e Silva A. Effectiveness of oseltamivir in reducing COVID-19-related in-hospital deaths: a pharmacoepidemiological study. Int. J Antimicrob Agents 2024;63(4):7. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107111","DOI":"10.1016\/j.ijantimicag.2024.107111"},{"issue":"4","key":"12327_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/ehjcvp\/pvac018","volume":"8","author":"J Wu","year":"2022","unstructured":"Wu J, Zhao M, Wei H, Li, et al. Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis. EHJ-CVP. 2022;8(4):392\u2013401. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac018.","journal-title":"EHJ-CVP"},{"key":"12327_CR13","doi-asserted-by":"publisher","unstructured":"Sportiello L, Capuano A. It is the time to change the paradigms of pregnant and breastfeeding women in clinical research! Front. Pharmacol. 2023;14:6. https:\/\/doi.org\/10.3389\/fphar.2023.1113557","DOI":"10.3389\/fphar.2023.1113557"},{"key":"12327_CR14","unstructured":"Ministry of Health (Brazil). SRAG, 2020 - Banco de Dados de S\u00edndrome Respirat\u00f3ria Aguda Grave - incluindo dados da COVID-19. https:\/\/opendatasus.saude.gov.br\/dataset\/srag-2020. Accessed 1 Dec 2024."},{"key":"12327_CR15","doi-asserted-by":"publisher","unstructured":"Hojo-Souza N, Guidoni D, Da Silva C, De Souza F. A temporal study of Brazilian pregnant and postpartum women vulnerability for COVID-19: characteristics, risk factors and outcomes. Lancet Reg Health Am. 2022;9:11. https:\/\/doi.org\/10.1016\/j.lana.2022.100197","DOI":"10.1016\/j.lana.2022.100197"},{"key":"12327_CR16","doi-asserted-by":"publisher","unstructured":"Diniz D, Brito L, Rondon G. Maternal mortality and the lack of women-centered care in Brazil during COVID-19: preliminary findings of a qualitative study. Lancet Reg Health Am. 2022;10:3. https:\/\/doi.org\/10.1016\/j.lana.2022.100239","DOI":"10.1016\/j.lana.2022.100239"},{"key":"12327_CR17","unstructured":"Angecia Brasil. Brazil sanitary agency Anvisa approves new drug for COVID-19 treatment. (Published 31 Mar 2022). https:\/\/agenciabrasil.ebc.com.br\/en\/saude\/noticia\/2022-03\/anvisa-approves-new-drug-treatment-covid-19. Accessed 10 Jul 2024."},{"issue":"8","key":"12327_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","volume":"147","author":"J Vandenbroucke","year":"2007","unstructured":"Vandenbroucke J, Elm E, Altman D, Gotzsche P, Mulrow C, Pocock S. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):163\u201394.","journal-title":"Ann Intern Med"},{"issue":"1","key":"12327_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3201\/eid2901.220530","volume":"29","author":"C Leung","year":"2023","unstructured":"Leung C, Su L, Sim\u00f5es-E-Silva A, Arocha L, de Paiva K, Haas P. Risk for severe illness and death among pediatric patients with down syndrome hospitalised for COVID-19, Brazil. Emerg. Infect. Dis. 2023;29(1):26\u201335. https:\/\/doi.org\/10.3201\/eid2901.220530.","journal-title":"Emerg Infect Dis"},{"key":"12327_CR20","unstructured":"Centers for Disease Control and Prevention (U.S.). COVID-19 treatments and medications 2024. https:\/\/www.cdc.gov\/covid\/treatment\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/your-health\/treatments-for-severe-illness.html. Accessed 1 Dec 2024."},{"issue":"8","key":"12327_CR21","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/aje\/kwab028","volume":"190","author":"C Renoux","year":"2021","unstructured":"Renoux C, Azoulay L, Suissa S. Biases in evaluating the safety and effectiveness of drugs for the treatment of covid-19: designing real-world evidence studies. Am J Epidemiol. 2021;190(8):1452\u201356. https:\/\/doi.org\/10.1093\/aje\/kwab028.","journal-title":"Am J Epidemiol"},{"issue":"8","key":"12327_CR22","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","volume":"20","author":"WHO","year":"2020","unstructured":"WHO. Working group on the clinical characteristics and management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192\u20137. https:\/\/doi.org\/10.1016\/S1473-3099(20)30483-7.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"12327_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","volume":"25","author":"E Stuart","year":"2010","unstructured":"Stuart E. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25(1):1\u201321. https:\/\/doi.org\/10.1214\/09-STS313.","journal-title":"Stat Sci"},{"key":"12327_CR24","doi-asserted-by":"publisher","unstructured":"Siqueira T, Silva J, Souza M, et al. Spatial clusters, social determinants of health and risk of maternal mortality by COVID-19 in Brazil: a national population-based ecological study. Lancet Reg Health Am. 2021;3:8. https:\/\/doi.org\/10.1016\/j.lana.2021.100076","DOI":"10.1016\/j.lana.2021.100076"},{"issue":"13","key":"12327_CR25","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/1471-0528.16470","volume":"127","author":"M Takemoto","year":"2020","unstructured":"Takemoto M, Menezes M, Andreucci C, et al. Clinical characteristics and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance database analysis. BJOG. 2020;127(13):1618\u201326. https:\/\/doi.org\/10.1111\/1471-0528.16470.","journal-title":"BJOG"},{"key":"12327_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(22)02467-9","volume":"401","author":"J Villar","year":"2023","unstructured":"Villar J, Conti C, Gunier R, Ariff S, Craik R, Cavoretto P. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. Lancet. 2023;401:447\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(22)02467-9.","journal-title":"Lancet"},{"key":"12327_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"P Austin","year":"2011","unstructured":"Austin P. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","journal-title":"Multivar Behav Res"},{"key":"12327_CR28","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/aje\/kwq224","volume":"172","author":"P Austin","year":"2010","unstructured":"Austin P. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010;172:1092\u201397. https:\/\/doi.org\/10.1093\/aje\/kwq224.","journal-title":"Am J Epidemiol"},{"key":"12327_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/sim.8008","volume":"38","author":"P Austin","year":"2018","unstructured":"Austin P, Fine J. Propensity-score matching with competing risks in survival analysis. Stat Med. 2018;38:751\u201377. https:\/\/doi.org\/10.1002\/sim.8008.","journal-title":"Stat Med"},{"key":"12327_CR30","doi-asserted-by":"crossref","unstructured":"Tenorio D, Brasil A, Nogueira B, Lima N, Araujo J, Neto M. High maternal mortality rates in Brazil: inequalities and the struggle for justice. Lancet Reg Health Am. 2022;14:2p.","DOI":"10.1016\/j.lana.2022.100343"},{"issue":"4","key":"12327_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S2213-2600(20)30560-9","volume":"9","author":"O Ranzani","year":"2021","unstructured":"Ranzani O, Bastos L, Gelli J, et al. Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. Lancet Respir Med. 2021;9(4):407\u201318. https:\/\/doi.org\/10.1016\/S2213-2600(20)30560-9.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"12327_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ajog.2022.05.020","volume":"227","author":"E Kalafat","year":"2022","unstructured":"Kalafat E, Heath P, Prasad S, O\u2018brien P, Khalil A. COVID-19 vaccination in pregnancy. AJOG. 2022;227(2):136\u201347. https:\/\/doi.org\/10.1016\/j.ajog.2022.05.020.","journal-title":"Ajog"},{"issue":"12","key":"12327_CR33","doi-asserted-by":"publisher","first-page":"e0277206","DOI":"10.1371\/journal.pone.0277206","volume":"17","author":"B Aliyu","year":"2022","unstructured":"Aliyu B, Raja Y, Chee H, Wong M, Sekawi B. Systematic review and meta-analysis of the efficacy and safety of oseltamivir (Tamiflu) in the treatment of coronavirus disease 2019 (COVID-19). PLoS One. 2022;17(12):e0277206. https:\/\/doi.org\/10.1371\/journal.pone.0277206.","journal-title":"PLoS One"},{"key":"12327_CR34","doi-asserted-by":"publisher","unstructured":"Harless W, Lewis B, Qorri B, Abdulkhalek S, Szewczuk M. Novel therapeutic target critical for SARS-CoV-2 infectivity and induction of the cytokine release syndrome. Cells. 2023;12(9):22. https:\/\/doi.org\/10.3390\/cells12091332","DOI":"10.3390\/cells12091332"},{"issue":"11","key":"12327_CR35","first-page":"1460","volume":"180","author":"R Formiga","year":"2023","unstructured":"Formiga R, Amaral F, Souza C, Mendes D, Wanderley C, Lorenzini C, et al. Neuraminidase is a host-directed approach to regulate neutrophil responses in sepsis and COVID-19. BJP. 2023;180(11):1460\u201381.","journal-title":"BJP"},{"issue":"6","key":"12327_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.mayocpiqo.2020.09.010","volume":"4","author":"R Stevens","year":"2020","unstructured":"Stevens R, Rivera C, Saleh O. Time to treat: applying lessons learned from other viral syndromes to SARS-CoV-2. Mayo Clin Proc Inn Qual Out. 2020;4(6):759\u201363. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2020.09.010.","journal-title":"Mayo Clin Proc Inn Qual Out"},{"key":"12327_CR37","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1473-3099(22)00507-2","volume":"22","author":"C Wong","year":"2022","unstructured":"Wong C, Au I, Lau K, Lau E, Cowling B, Leung G. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong\u2019s omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;22:1681\u201393. https:\/\/doi.org\/10.1016\/S1473-3099(22)00507-2.","journal-title":"Lancet Infect Dis"},{"key":"12327_CR38","doi-asserted-by":"publisher","unstructured":"Testa C, Godoi L, Monroy N, Bortolotto M, Rodrigues A, Francisco R. Impact of Gamma COVID-19 variant on the prognosis of hospitalized pregnant and postpartum women with cardiovascular disease. Clinics. 2024;79:7. https:\/\/doi.org\/10.1016\/j.clinsp.2024.100454","DOI":"10.1016\/j.clinsp.2024.100454"},{"key":"12327_CR39","doi-asserted-by":"publisher","unstructured":"Gon\u00e7alves B, Franco R, Rodrigues A. Maternal mortality associated with COVID-19 in Brazil in 2020 and 2021: comparison with non-pregnant women and men. PLoS One. 2021;16(12):15. https:\/\/doi.org\/10.1371\/journal.pone.0261492","DOI":"10.1371\/journal.pone.0261492"},{"key":"12327_CR40","doi-asserted-by":"crossref","unstructured":"Kadiwar S, Smith J, Ledot S, Johnson M, Bianchi P, Singh N, et al. Were pregnant women more affected by COVID-19 in the second wave of the pandemic? Lancet. 2021;397:1539\u201340.","DOI":"10.1016\/S0140-6736(21)00716-9"},{"key":"12327_CR41","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/s41591-022-01807-1","volume":"28","author":"A Brizzi","year":"2022","unstructured":"Brizzi A, Whittaker C, Servo L, Hawryluk I, Prete C, Souza W, et al. Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals. Nat Med. 2022;28:1476\u201385. https:\/\/doi.org\/10.1038\/s41591-022-01807-1.","journal-title":"Nat Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12327-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12327-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12327-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:29:46Z","timestamp":1781623786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12327-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12327"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12327-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study used publicly available, anonymised data, ethical approval was therefore not required for this study in neither Brazil nor the United Kingdom.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}